Clinical Trials
6 trialsNCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT06274879 2026-05-26
Ablatio
Insel Gruppe AG, University Hospital Bern
Phase 2 Recruiting
NCT05655949 2026-04-22
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT04298008 2024-04-19
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Unknown
NCT04298021 2024-04-19
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Unknown
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed